TherapeuticsMD, Inc. (TXMD): Price and Financial Metrics


TherapeuticsMD, Inc. (TXMD): $0.31

-0.03 (-7.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TXMD POWR Grades


  • TXMD scores best on the Growth dimension, with a Growth rank ahead of 72.75% of US stocks.
  • TXMD's strongest trending metric is Momentum; it's been moving up over the last 112 days.
  • TXMD's current lowest rank is in the Momentum metric (where it is better than 8.78% of US stocks).

TXMD Stock Summary

  • TherapeuticsMD Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 3.64% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -3.51 for TherapeuticsMD Inc; that's greater than it is for just 3.12% of US stocks.
  • TherapeuticsMD Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -110.68%, greater than the shareholder yield of only 3.52% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to TherapeuticsMD Inc, a group of peers worth examining would be NR, TELA, CUEN, GNLN, and ACA.
  • TXMD's SEC filings can be seen here. And to visit TherapeuticsMD Inc's official web site, go to www.therapeuticsmd.com.

TXMD Valuation Summary

  • TXMD's price/sales ratio is 4; this is 64.76% lower than that of the median Healthcare stock.
  • TXMD's price/earnings ratio has moved up 14.2 over the prior 115 months.
  • Over the past 115 months, TXMD's EV/EBIT ratio has gone up 13.2.

Below are key valuation metrics over time for TXMD.

Stock Date P/S P/B P/E EV/EBIT
TXMD 2021-08-31 4.0 -6.9 -2.1 -3.4
TXMD 2021-08-30 4.0 -6.9 -2.2 -3.4
TXMD 2021-08-27 4.0 -7.0 -2.2 -3.4
TXMD 2021-08-26 4.0 -7.0 -2.2 -3.4
TXMD 2021-08-25 4.1 -7.1 -2.2 -3.5
TXMD 2021-08-24 4.1 -7.1 -2.2 -3.5

TXMD Growth Metrics

    Its 4 year cash and equivalents growth rate is now at -6.59%.
  • Its 4 year revenue growth rate is now at 181.34%.
  • The year over year revenue growth rate now stands at 25.08%.
Over the past 67 months, TXMD's revenue has gone up $70,252,845.

The table below shows TXMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 90.85079 -133.4563 -171.5426
2021-06-30 84.78759 -129.282 -156.7337
2021-03-31 72.48762 -158.7394 -166.0583
2020-12-31 64.87228 -159.4703 -183.5241
2020-09-30 58.19617 -179.9463 -190.8721
2020-06-30 62.57311 -172.1202 -190.2276

TXMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TXMD has a Quality Grade of D, ranking ahead of 19.35% of graded US stocks.
  • TXMD's asset turnover comes in at 0.419 -- ranking 109th of 682 Pharmaceutical Products stocks.
  • ALNY, QGEN, and CASI are the stocks whose asset turnover ratios are most correlated with TXMD.

The table below shows TXMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.419 0.791 -0.569
2021-03-31 0.361 0.752 -0.564
2020-12-31 0.311 0.754 -0.620
2020-09-30 0.254 0.772 -0.681
2020-06-30 0.253 0.817 -0.738
2020-03-31 0.225 0.857 -0.822

TXMD Price Target

For more insight on analysts targets of TXMD, see our TXMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.80 Average Broker Recommendation 1.38 (Strong Buy)

TXMD Stock Price Chart Interactive Chart >

Price chart for TXMD

TXMD Price/Volume Stats

Current price $0.31 52-week high $2.75
Prev. close $0.34 52-week low $0.31
Day low $0.31 Volume 4,157,000
Day high $0.34 Avg. volume 8,695,014
50-day MA $0.45 Dividend yield N/A
200-day MA $0.85 Market Cap 132.87M

TherapeuticsMD, Inc. (TXMD) Company Bio


TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, as well as duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. The company was founded in 2008 and is based in Boca Raton, Florida.


TXMD Latest News Stream


Event/Time News Detail
Loading, please wait...

TXMD Latest Social Stream


Loading social stream, please wait...

View Full TXMD Social Stream

Latest TXMD News From Around the Web

Below are the latest news stories about TherapeuticsMD Inc that investors may wish to consider to help them evaluate TXMD as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 6, 2022

FDA Approves TherapeuticsMD's Low Dose Bijuva

TherapeuticsMD Inc (NASDAQ: TXMD) is trading sharply higher after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause. In a regulatory filing, TherapeuticsMD said that on December 28, the agency cleared its supplemental marketing application for Bijuva, seeking approval for the capsule at the 0.5 mg/100 mg dose level. Related Link: TherapeuticsMD, Amneal Settle US Patent Litigation For Bijuva. The plans

Yahoo | January 4, 2022

Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options

Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

Yahoo | December 28, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, investor!

William White on InvestorPlace | December 13, 2021

TherapeuticsMD's Birth Control Med Receives FDA Response Letter To Revise Manufacturing Testing Limits

TherapeuticsMD Inc (NASDAQ: TXMD) said that the FDA could not approve revisions to certain manufacturing testing limits for Annovera through the supplemental marketing application previously submitted by the Company. The supplemental application requested minor revisions to the in vitro release testing specification for Annovera to allow for normal commercial manufacturing variation. Also, see Benzinga's Full FDA Calendar here. The Company submitted the proposed revisions to the manufacturing te

Yahoo | December 13, 2021

Read More 'TXMD' Stories Here

TXMD Price Returns

1-mo N/A
3-mo -59.42%
6-mo -69.61%
1-year -79.33%
3-year -94.11%
5-year -94.50%
YTD -12.80%
2021 -70.62%
2020 -50.00%
2019 -36.48%
2018 -36.92%
2017 4.68%

Continue Researching TXMD

Here are a few links from around the web to help you further your research on TherapeuticsMD Inc's stock as an investment opportunity:

TherapeuticsMD Inc (TXMD) Stock Price | Nasdaq
TherapeuticsMD Inc (TXMD) Stock Quote, History and News - Yahoo Finance
TherapeuticsMD Inc (TXMD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8417 seconds.